Results 241 to 250 of about 1,442,988 (353)

Synthesis and Evaluation of an Anti-MLC1 × Anti-CD90 Bispecific Antibody for Targeting and Retaining Bone-Marrow-Derived Multipotent Stromal Cells in Infarcted Myocardium [PDF]

, 2011
C. William Gundlach, Amy R. Caivano, Maria da Graça Cabreira-Hansen, Amir Gahremanpour, Wells S. Brown, Yi Zheng, Bradley W. McIntyre, James T. Willerson, Richard A. F. Dixon, Emerson C. Perin, Darren G. Woodside   +10 more
openalex   +1 more source

Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 100, Issue 5, Page 860-891, May 2025.
ABSTRACT Disease Overview Acute myeloid leukemia (AML) is a bone marrow stem cell cancer that is often fatal despite available treatments. Diagnosis, risk assessment, monitoring, and therapeutic management of AML have changed dramatically in the last decade due to increased pathophysiologic understanding, improved assessment technology, and the ...
Shai Shimony, Maximilian Stahl, Richard M. Stone   +2 more
wiley   +1 more source

Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada. [PDF]

Curr Oncol
Fleury I, MacDonald D, Shafey M, Christofides A, Sehn LH.   +4 more
europepmc   +1 more source

Targeted delivery of radioisotope or chemotherapeutic loaded prodrug-polymers after pretargeting tumors with bispecific antibody complex [PDF]

, 2011
Keyur Gada
openalex   +1 more source

Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma (TRUST): A Multicenter, Single‐Arm, Phase 2 Trial

Cancer Medicine, Volume 14, Issue 9, May 2025.
ABSTRACT Background Histone deacetylase (HDAC) inhibitors demonstrated a synergistic anti‐tumor effect with rituximab and chemotherapy in preclinical studies on diffuse large B‐cell lymphoma (DLBCL). This phase 2 trial aimed to evaluate the efficacy and safety of chidamide, an orally active HDAC inhibitor, plus the R‐GemOx regimen for relapsed ...
Qihua Zou, Yuchen Zhang, Hui Zhou, Yulin Lai, Yi Cao, Zhiming Li, Ning Su, Wenyu Li, Huiqiang Huang, Panpan Liu, Xu Ye, Yudan Wu, Huo Tan, Runhui Zheng, Bingyi Wu, Hui Yang, Liye Zhong, Yuhong Lu, Yang Liang, Peng Sun, Lirong Li, Yingxian Liu, Danling Dai, Yi Xia, Qingqing Cai   +24 more
wiley   +1 more source

Design of orthogonal constant domain interfaces to aid proper heavy/light chain pairing of bispecific antibodies. [PDF]

MAbs
Barlow KA, Battles MB, Brown ME, Canfield K, Lu X, Lynaugh H, Morrill M, Rappazzo CG, Reyes SP, Sandberg C, Sharkey B, Strong C, Zhao J, Sivasubramanian A.   +13 more
europepmc   +1 more source

Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site [PDF]

, 2012
Thomas List, Dario Neri
openalex   +1 more source

Alternative Immunosuppression in Acquired Haemophilia A

Haemophilia, EarlyView.
Jayna Mistry, Gillian Lowe, Will Lester, Charles Percy   +3 more
wiley   +1 more source

Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma

Clinical Pharmacology &Therapeutics, Volume 117, Issue 5, Page 1437-1450, May 2025.
Epcoritamab is a CD3xCD20 bispecific antibody that activates T cells to kill CD20‐expressing B cells. Epcoritamab is approved for the treatment of adults with different types of relapsed or refractory lymphoma in various geographies, including the United States, Europe, and Japan.
Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Matthew Putnins, Christopher W. Chiu, Mariana Sacchi, Huaibao Feng, Tahamtan Ahmadi, Manish Gupta, Steven Xu   +9 more
wiley   +1 more source

Bispecific antibodies and CLEM: an analytical approach to advanced cell imaging for therapeutic strategies. [PDF]

Appl Microsc
Kim HU, Kim YK.
europepmc   +1 more source